Dernek Hakkında Tıbbi Onkoloji Derneği Haberler

Annals of Oncology - Ekim 2010


A. Psyrri,  L. Licitra,  D. Lacombe,  E. Schuuring,  W. Budach,  M. Ozsahin,  R. Knecht,  J. B. Vermorken,  and J. A. Langendijk

Strategies to promote translational research within the European Organisation for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group: a report from the Translational Research Subcommittee Ann Oncol (2010) 21(10): 1952-1960 first published online March 19, 2010 doi:10.1093/annonc/mdq060  Abstract
Original Articles
R. Mesía,  F. Rivera,  A. Kawecki,  S. Rottey,  R. Hitt,  H. Kienzer,  D. Cupissol,  D. De Raucourt,  M. Benasso,  P. Koralewski,  J.-P. Delord,  C. Bokemeyer,  D. Curran,  A. Gross,  and J. B. Vermorken Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck Ann Oncol (2010) 21(10): 1967-1973 first published online March 24, 2010 doi:10.1093/annonc/mdq077
B. F. El-Rayes, M. Zalupski,  T. Bekai-Saab,  L. K. Heilbrun,  N. Hammad,  B. Patel,  S. Urba,  A. F. Shields,  U. Vaishampayan,  S. Dawson,  K. Almhanna,  D. Smith,  and P. A. Philip
A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers  Ann Oncol (2010) 21(10): 1999-2004 first published online March 23, 2010 doi:10.1093/annonc/mdq065  Abstract
P. Gascon,  R. Pirker,  L. Del Mastro,  and L. Durrwell
Effects of CERA (continuous erythropoietin receptor activator) in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemotherapy: results of a phase II study Ann Oncol (2010) 21(10): 2029-2039 first published online March 24, 2010 doi:10.1093/annonc/mdq073
A. Jatoi, S. E. Schild, N. Foster, G. T. Henning, K. J. Dornfeld, P. J. Flynn, T. R. Fitch, S. R. Dakhil, K. M. Rowland, P. J. Stella, G. S. Soori, and A. A. Adjei
A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422)
Ann Oncol (2010) 21(10): 2040-2044 first published online June 21, 2010 doi:10.1093/annonc/mdq075
K. Behringer, L. Wildt, H. Mueller, V. Mattle, P. Ganitis, B. van den Hoonaard, H. W. Ott, S. Hofer, A. Pluetschow, V. Diehl, A. Engert, P. Borchmann, and on behalf of the German Hodgkin Study Group
No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group
T. J. Price, A. R. Townsend, and A. Khattak
Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomised phase II study
Ann Oncol (2010) 21(10): 2121 doi:10.1093/annonc/mdq450
K. Bujko, R. Glynne-Jones, and M. Bujko
Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials
P. D. Mozley, L. H. Schwartz, C. Bendtsen, B. Zhao, N. Petrick, and A. J. Buckler
Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidence
Ann Oncol (2010) 21(9): 1751-1755 first published online March 23, 2010 doi:10.1093/annonc/mdq051
N. Reddy and M. S. Czuczman
Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies
Ann Oncol (2010) 21(9): 1756-1764 first published online February 4, 2010 doi:10.1093/annonc/mdq009
Original Reports
M. Reck, J. von Pawel, P. Zatloukal, R. Ramlau, V. Gorbounova, V. Hirsh, N. Leighl, J. Mezger, V. Archer, N. Moore, C. Manegold, and BO17704 Study Group
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
Ann Oncol (2010) 21(9): 1804-1809 first published online February 11, 2010 doi:10.1093/annonc/mdq020
P. Zatloukal, F. Cardenal, A. Szczesna, V. Gorbunova, V. Moiseyenko, X. Zhang, L. Cisar, J.-C. Soria, M. Domine, and M. Thomas
A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease
Ann Oncol (2010) 21(9): 1810-1816 first published online March 15, 2010 doi:10.1093/annonc/mdq036
A. C. Vilmar, E. Santoni-Rugiu, and J. B. Sørensen
ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial
Ann Oncol (2010) 21(9): 1817-1824 first published online March 23, 2010 doi:10.1093/annonc/mdq053